Prohibits pharmacy benefits managers from operating pharmacy practice sites directly or indirectly.
Impact
If enacted, SB 4717 will significantly change the regulatory framework for pharmacy operations in the state. Starting from July 1, 2027, PBMs will be barred from acquiring any direct or indirect interest in or permits for pharmacy practice sites. The provisions of the bill further mandate that the New Jersey State Board of Pharmacy conduct a thorough review of current pharmacy practice permits, providing notifications to impacted sites to ensure compliance. Additionally, there are allowances for special permits for certain rare or limited distribution drugs, aiming to mitigate potential shortages while strictly regulating PBM participation in pharmacy operations.
Summary
Senate Bill 4717 aims to prohibit pharmacy benefits managers (PBMs) from operating pharmacy practice sites within New Jersey. This legislation is introduced with the intent to support better patient access to prescription medications and pharmacy services at fair prices. The bill highlights the findings of both the Federal Trade Commission and the United States House Committee on Oversight and Government Reform, which have identified anticompetitive practices by PBMs that have led to the decline of locally-operated pharmacies. The legislation is designed to curb these practices and address the resulting issues of inflated drug prices and limited patient choices in the pharmaceutical market.
Contention
The introduction of SB 4717 is expected to generate discussions around the balance between regulating pharmacy benefits managers and ensuring patient access to necessary medications. Proponents argue that prohibiting PBMs from owning pharmacies will enhance competition and lower drug prices, directly benefiting consumers. However, potential concerns may arise regarding the accessibility of certain medications, especially for rare or specialty drugs, as the bill allows for special permits to address this issue. As stakeholders analyze these implications, the bill could spark debates on whether restrictions might hinder pharmaceutical innovation and market responsiveness in the state.
Provides for fair pharmacy reimbursement from a pharmacy benefit manager, and also provides anti-discrimination prohibitions in regard to non-affiliated pharmacies or pharmacists.
Provides for fair pharmacy reimbursement from a pharmacy benefit manager, and also provides anti-discrimination prohibitions in regard to non-affiliated pharmacies or pharmacists.